Pump Thrombosis
Pump Thrombosis - Related Videos
10:37
Ferric Chloride-induced Murine Thrombosis Models
0 Views •
Cited by 56 •
2016
We report a refined procedure of the ferric chloride (FeCl3)-induced thrombosis models on carotid and mesenteric artery as well as vein, characterized efficiently using intravital microscopy to monitor time to occlusive thrombi formation.
10:26
A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
0 Views •
Cited by 5 •
2015
The goal of this study is to use magnetic resonance venography with long-circulating gadolinium-based contrast agent and direct thrombus imaging for quantitative evaluation of DVT volume in a multicenter, clinical trial setting. Inter- and intra-observer variability assessments were conducted, and reproducibility of the protocol was determined.
01:30
ATP Driven Pumps III: V-type Pumps
0 Views •
2023
V-type pumps are ATP-driven pumps found in the vacuolar membranes of plants, yeast, endosomal and lysosomal membranes of animal cells, plasma membranes of a few specialized eukaryotic cells, and some prokaryotes. They are also known as the V1Vo-ATPase, that couple ATP hydrolysis to transport protons against a concentration gradient. The peripheral or cytosolic V1 domain with eight subunits is involved in ATP hydrolysis. The integral or transmembrane V0 domain containing at least five subunits...
01:34
ATP Driven Pumps II: P-type Pumps
0 Views •
2023
The P-type pumps are a large family of integral membrane transporter ATPases. They are divided into five major types based on substrate specificity, from I to V. A typical P-type pump has three cytosolic domains: nucleotide-binding (N), phosphorylation (P), and activator (A) domains. These domains are connected to the membrane-spanning helices by short amino acid segments. ATP hydrolysis and covalent phosphoenzyme intermediate formation are crucial parts of the catalytic cycle. At the highly...
04:34
Mouse Complete Stasis Model of Inferior Vena Cava Thrombosis
0 Views •
Cited by 28 •
2011
The mouse complete stasis model of inferior vena cava thrombosis yields quantifiable amounts of vein wall tissue and thrombus. It has proven useful for evaluating interactions between the vein wall and the occlusive thrombus and in assessing the progression from acute to chronic inflammation.
FAQs
Blood-contacting surfaces, altered flow, and stasis can shift the pump environment toward coagulation. When blood encounters these conditions, coagulation activation can support initial thrombus formation, while reduced movement allows clot material to persist and grow. This interaction explains why both device-fluid dynamics and local blood residence matter in the process.
Abnormal shear forces provide a separate mechanism of injury. As a thrombus changes the way blood moves through the pump, the resulting force pattern can damage blood cells, producing hemolysis. Thus, clot-related harm may arise not only from physical blockage, but also from blood-cell injury associated with disturbed mechanical conditions inside the device.
The clinical consequences depend on how much the clot disrupts pump performance. Obstruction can reduce effective support, while mechanical blood-cell damage can contribute to hemolysis. These effects may appear alongside changes in measured power or flow and symptoms suggesting reduced support, making device performance and patient status complementary indicators.
Monitoring for suspected pump thrombosis may combine device and patient information. Clinicians may examine power and flow measurements, assess hemolysis markers, and look for symptoms of reduced support. This approach spans mechanical performance, blood-cell injury, and clinical status, linking a possible internal pump problem with its effects on the patient.
Early recognition is important because management can range from medical to procedural intervention. Depending on the clinical situation, the response may include anticoagulation, medical treatment, device exchange, or urgent intervention. The purpose is to address the suspected clot while responding to impaired pump function and the potential threat to patient safety.
In ventricular assist devices, pump thrombosis is especially consequential because the pump contributes directly to circulatory support. The same concern also applies to other blood pumps with blood-contacting surfaces. In both settings, clinicians must relate evidence of altered pump performance, hemolysis, or reduced support to a possible device-related thrombotic complication.